-
Wyeth Pharmaceuticals has received approval to market desvenlafaxine for the treatment of depression. The drug is the major active metabolite of venlafaxine (Effexor ). Wyeth has formulated the drug in a once-daily extended-release tablet. It will be marketed under the trade name Pristiq.
-
Lower serum testosterone in men aged 60 and over was associated with increased fracture risk (especially hip and nonvertebral), even after adjusting for other major risk factors for fracture.
-
Neither training in working techniques nor use of lifting equipment appears to prevent back pain or back-related disability.
-
This single center prospective observational study finds that the utility of a routine daily chest x-ray (CXR) for an ICU patient is quite limited. A change in practice to ordering CXR only when clinically indicated did not adversely impact patient outcome but reduced CXR volume and overall costs.
-
The greatest challenge for any potentially mortal disorder is to prove that therapeutic interventions reduce not only disease-specific mortality, but also all-cause mortality.
-
Duct tape is no more effective than moleskin for the treatment of common warts. Occlusion therapy with both for 7 days will give resolution in just over 20% of patients.
-
Increasing use of CT scans has led to an increase of radiation exposure to its recipients, potentially causing up to 2% of new cancers, especially in children.
-
The FDA has approved extended release niacin plus simvastatin as a combination product.
-
Does Published Evidence Reflect the Whole Story?, Vitamin E levels and Physical Decline with Aging, Effort, Efficacy, and Effectiveness
-
The onset of dementia heralds death in about 41/2 years.
